Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | +6.67% |
|
-4.19% | -15.79% |
06-06 | I-Mab Appoints Phillip Dennis as Chief Medical Officer | CI |
06-05 | I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.79% | 129M | |
+56.89% | 823B | |
+40.51% | 627B | |
-6.55% | 353B | |
+15.99% | 320B | |
+7.92% | 295B | |
+13.85% | 239B | |
+13.56% | 220B | |
-0.57% | 219B | |
+7.94% | 167B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-Mab's Phase 3 Trial of Growth Hormone Deficiency Drug Meets Primary Endpoint, Joint Venture Partner Says